Maymetsi

Metformin Hydrochloride / Sitagliptin, the active ingredient in Maymetsi, is a Biguanide / DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maymetsi is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Inadequate control on metformin alone: provides additional glucose‑lowering effect when metformin monotherapy is insufficient. - Combination therapy: used together with insulin or other oral agents to achieve target HbA1c levels.

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: can lead to loss of consciousness. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, pruritus, or angio‑edema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Maymetsi, clinicians should evaluate patient‑specific risk factors and monitor regularly. - Renal function: assess eGFR and avoid use in severe renal impairment. - Lactic acidosis risk: contraindicated in patients with significant hepatic disease. - Hypoglycaemia risk: monitor closely when used with insulin or sulfonylureas. - Cardiovascular disease: use with caution in unstable heart conditions. - Pregnancy and lactation: weigh benefits against potential risks; consult prescriber. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Maymetsi may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Iodinated contrast agents: may precipitate renal dysfunction with metformin. - Cimetidine: can raise metformin plasma concentrations. - Rifampicin: reduces sitagliptin exposure, diminishing efficacy. - Alcohol: may potentiate lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: affect renal clearance of metformin. - ACE inhibitors: require renal function monitoring. - Warfarin: possible alteration of INR values. - Corticosteroids: may increase blood glucose levels.